Related Experiment Video
Updated: May 17, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Antiglaucoma pharmacotherapy
1Ophthalmology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. calintataru1@yahoo.com
Journal of Medicine and Life
|October 11, 2012
Summary
This review explores treatments for glaucomatous optic neuropathy, focusing on lowering intraocular pressure and novel retinal ganglion cell neuroprotection strategies. Future therapies aim to combine these approaches for improved optic nerve survival and ocular health.
Area of Science:
- Ophthalmology
- Pharmacology
- Neuroscience
Background:
- Glaucomatous optic neuropathy is a complex condition with multiple contributing factors.
- Current primary treatment involves reducing intraocular pressure.
- Emerging research focuses on neuroprotection of retinal ganglion cells.
Purpose of the Study:
- To review available pharmacotherapeutic strategies for glaucomatous optic neuropathy.
- To highlight the shift towards neuroprotective treatments.
- To discuss the ideal characteristics of future glaucoma therapies.
Main Methods:
- Literature review of current and developing pharmacotherapies for glaucoma.
- Analysis of neuroprotection mechanisms, including cell survival and apoptosis inhibition.
- Consideration of factors like ocular hemodynamics and patient compliance.
Main Results:
- Pharmacotherapy currently centers on lowering intraocular pressure.
- Neuroprotection strategies are a significant trend, combining antihypertensive agents with neuroprotective drugs.
- Effective treatments must also consider ocular blood flow and minimize side effects.
Conclusions:
- Future pharmacotherapeutic approaches for glaucomatous optic neuropathy will likely integrate intraocular pressure reduction with direct optic nerve protection.
- The goal is to enhance retinal ganglion cell survival and preserve vision.
- Optimal treatment requires a multi-faceted approach addressing hemodynamics, compliance, and safety.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications